Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data from the AVONELLE-X and SALWEEN ...

Genentech’s initial investment in North Carolina is estimated at more than $700m and is part of Roche’s $50bn commitment to ...

OMass Therapeutics partners with Genentech to advance innovative treatments for inflammatory bowel disease, leveraging their ...

Oxford, UK-based biotech OMass Therapeutics today announced it has entered into an exclusive collaboration and license ...

Eli Lilly and Novo Nordisk already produce popular GLP-1s in the Triangle. A Swiss drugmaker says its future Wake County site ...

Roche’s Genentech unit has handed over $20 million in upfront cash for the license to Omass Therapeutics’ preclinical inflammatory bowel disease (IBD) program. | Roche’s Genentech unit has handed over ...

Generative AI, once seen as a tool for writers and artists, is now reshaping the high-stakes world of pharma regulation.

Research from Deloitte has shown that 82% of CEOs report burnout and 96% report a negative impact on their mental health.

Biotechnology pioneer Genentech broke ground Monday on a $700 million manufacturing facility in Holly Springs, marking the ...

San Francisco-based Genentech plans to create up to 420 high-paying jobs in Holly Springs — a project expected to bring an ...

Genentech, a member of the Roche Group, has commenced construction of a new manufacturing site in Holly Springs, North ...

Collaboration leverages OMass’ OdyssionTM platform for the continued development of oral small molecules against a ...